Initial experience with bosentan therapy in patients with the Eisenmenger syndrome

The American Journal of Cardiology
Douglas D ChristensenWilliam T Mahle

Abstract

Bosentan, an endothelin-1 antagonist that can be administered orally, has been shown to be effective in the treatment of idiopathic pulmonary arterial hypertension and may be of benefit to patients with the Eisenmenger syndrome. Nine patients with Eisenmenger's syndrome were treated with bosentan at a dose of 125 mg twice a day. After treatment with bosentan, 6 of 9 patients (67%) had an improvement in New York Heart Assocation classification of >/=1 grades (p = 0.03). Oxygen saturation levels increased from 79 +/- 5% to 88 +/- 6%, (p = 0.03). The side effects of bosentan therapy were minor; no significant changes in liver function tests were noted. These preliminary data suggest that oral administration of bosentan therapy for Eisenmenger's syndrome results in improved oxygenation and functional status with minimal side effects.

References

Apr 1, 1986·British Heart Journal·J J BowyerE A Shinebourne
Nov 24, 2001·American Journal of Respiratory and Critical Care Medicine·J SandovalE Bautista
Sep 18, 2002·Circulation·Vallerie V McLaughlinStuart Rich
Oct 26, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Boaz OvadiaJeffrey R Fineman

❮ Previous
Next ❯

Citations

May 27, 2006·Cardiology in the Young·Eugene KotlyarDavid S Celermajer
Apr 25, 2007·Cardiology in the Young·Henrik BrunHenrik Holmstrom
Mar 20, 2010·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Ian Adatia, Lara Shekerdemian
Aug 18, 2010·International Journal of Clinical Practice. Supplement·G-P Diller, H Baumgartner
Nov 28, 2013·Heart Failure Clinics·Alexander R OpotowskyMaurice Beghetti
Jul 4, 2012·Heart Failure Clinics·Vedant GuptaRichard A Krasuski
Feb 10, 2010·La Presse médicale·Philippe Acar
Jun 27, 2008·International Journal of Cardiology·Mariëlle G J DuffelsBarbara J M Mulder
Jul 31, 2007·International Journal of Cardiology·Michael A GatzoulisUNKNOWN BREATHE-5 Investigators
Aug 22, 2006·European Journal of Clinical Investigation·O SitbonG Simonneau
Apr 2, 2008·Congenital Heart Disease·Omid SalehianPeter Liu
Jan 27, 2005·The American Journal of Cardiology·Maurice BeghettiBeat Friedli
Jan 9, 2013·International Journal of Cardiology·Alexander Van De BruaeneWerner Budts
Oct 4, 2005·Expert Opinion on Pharmacotherapy·Werner Budts
Feb 28, 2009·Journal of the American College of Cardiology·Maurice Beghetti, Nazzareno Galiè
Mar 7, 2012·International Journal of Cardiology·Gerhard-Paul DillerMichael A Gatzoulis
Feb 5, 2015·Archivos de cardiología de México·Juan Calderón-ColmeneroMiguel Beltrán Gámez
Jun 28, 2006·Circulation·Nazzareno GalièUNKNOWN Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators
Mar 21, 2006·Current Opinion in Anaesthesiology·Reem M HajC David Mazer
Jul 31, 2013·Expert Review of Cardiovascular Therapy·Robert M RadkeHelmut Baumgartner
May 19, 2006·European Heart Journal·Tom AdriaenssensWerner Budts
Feb 8, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kazumi Fujimoto, Satoru Ikenoya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.